Why the study?
Renal denervation reduces central sympathetic overactivation, a process relevant to heart failure, warranting a summary of current evidence and future developments.
Renal denervation is being explored as a potential treatment for heart failure due to its ability to reduce central sympathetic overactivation.
Answers are grounded in this paper and cite their sources.
Renal denervation merits evaluation in HF trials targeting sympathetic drive; current evidence leaves open its clinical role.
Renal Denervation (RDN) has emerged over the last decade as a third pillar in the treatment of arterial hypertension, alongside pharmacotherapy and lifestyle modifications. Mechanistically, it reduces central sympathetic overactivation, a process also relevant to heart failure. In this mini-review, we summarize the development of RDN for heart failure, discuss the current evidence supporting its effects, and provide an outlook on future developments.
No takes yet. Share an insight, caveat, or question.
Koppe-Schmeißer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: